CD79A and Recurrent upper respiratory tract infections: Salivary IgA has the capacity to inhibit the colonization of pathogens, bind antigens for transport across the epithelial barrier, and neutralize viruses, representing one of the body’s first lines of defense against infections related to upper respiratory tract infection [56].